ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Amgen Agrees to Settle Aranesp Marketing Lawsuit, Reserves $780 Million For Settlement

October 28, 2011

Panel Calls For New Office, Advisory Groups To Oversee NCI’s Translational Research.

June 22, 2007

In Brief: NCI Still Undecided Over Small Hospital Segment Of CHOP; Multihospital Proposals Review Nov. 14-15

November 2, 1979

Scientists Brief Writers On Progress In Cancer Research

April 11, 1975

CCOPs Extended One Year While Waiting Evaluation

May 17, 1985

NCI Programs: 15 New Grants Awarded In Survivor Research

October 9, 1998